Harry Erba, MD, PhD:In looking at her presenting symptoms, physical exam, and blood counts, this is not at all atypical for patients. And in fact, patients like this may be seen by a number of specialists and primary care physicians before they actually get to the hematologist. So, if a blood count isn’t checked and they’re having abdominal fullness, night sweats, prurituswhich is quite common—or fatigue, a number of evaluations for other disorders might have ensued before finally getting to the blood count and showing that the problem is in the bone marrow. So, this is quite typical.
Now the natural history of myelofibrosis is quite varied. Some patients having a very long survival, and some much shorter. And a number of prognostic staging evaluations, or models, have been developed. The first that we’ve been using is Cervantes’ International Prognostic Score criteria, where there are 5 prognostic factors: age over the age of 65, which she has; presence of constitutional symptoms such fevers, night sweats, and weight loss, which she has; anemia with a hemoglobin under 10; leukocytosis with a white-blood cell count over 25,000; and the presence of more than 1% circulating blast. That’s the only one we don’t know that she has, but she has all of the other 4.
If you have none of those factors, then you have low-risk disease with a median survival that exceeds 10 years. However, most patients, 90% of patients, will have intermediate 1risk disease with 1 risk factor, intermediate-2 with 2 risk factors, or high-risk disease with 3 or more risk factors. The median survival gets progressively worse with each of those. For patients with high-risk disease, the median survival is only about 2 years.
Transcript edited for clarity.
March 2017
Savona Discusses First-Line JAK Inhibition for Patients With Myelofibrosis at Risk of Anemia
April 17th 2024During a Case-Based Roundtable® event, Michael Savona, MD, and participants discussed the case of a patient with myelofibrosis and moderate anemia receiving JAK inhibitor therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Scott Evaluates Treatment Options for Hydroxyurea-Resistant Polycythemia Vera
March 28th 2024In a Community Case Forum event in partnership with the Washington State Medical Oncology Society, Bart Scott, MD, broke down various trials of hydroxyurea, ruxolitinib, and interferon in patients with polycythemia vera to assess outcomes such as hematocrit control and molecular response.
Read More
Weighing the Triggers for Initiating JAK2 Inhibition Therapy in MF
March 23rd 2024During a Case-Based Roundtable® event, Raajit K. Rampal, MD, PhD, discussed the triggers physicians need to consider when deciding to initiate therapy for patients with myelofibrosis in the first article of a 2-part series.
Read More
Participants Discuss Treating a Patient With Myelofibrosis and Anemia
March 18th 2024During a Targeted Oncology™ Case-Based Roundtable™ event, Salman Fazal, MD, discussed with participants which symptoms of myelofibrosis impact their quality of life and how they would treat a patient experiencing anemia.
Read More